Cells organize their molecules into distinct functional areas. While textbooks usually refer to membrane-bound organelles ...
Three proteasome inhibitors (PIs) are approved for patients with multiple myeloma (MM): Bortezomib, a first-in class PI, fights both newly diagnosed and relapsed/refractory MM (RRMM); carfilzomib, a ...
QLi5 Therapeutics GmbH (QLi5), a spin-off from the Max Planck Institute for Biochemistry, has successfully completed a ...
he ubiquitin‒proteasome system (UPS) and autophagy are protein degradation pathways essential for maintaining protein balance and regulation, or proteostasis (left panel). When proteasome activity ...
Proteasome inhibitors have brought major advances in the treatment of multiple myeloma (MM), but eventual drug resistance remains a serious hurdle. Drug resistance continues to be a major problem in ...
The proteasome is a major proteolytic machine that regulates cellular proteostasis through selective degradation of ubiquitylated proteins. As the maintenance of protein homeostasis is essential to ...
Focal bone marrow processes and early bone lesions in patients with multiple myeloma (MM) precursor diseases: A prospective study using molecular imaging. This is an ASCO Meeting Abstract from the ...
Researchers from IOCB Prague are furthering the understanding of how medicines work and what it takes to develop their most effective variants. In one current study, they have focused on the disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results